Compare AEC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEC | LUNG |
|---|---|---|
| Founded | 1989 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 97.1M |
| IPO Year | 2011 | 2020 |
| Metric | AEC | LUNG |
|---|---|---|
| Price | $2.38 | $2.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 40.6K | ★ 1.3M |
| Earning Date | 05-01-2015 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $0.39 |
| Revenue Next Year | $48.15 | $8.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $2.31 | $1.13 |
| 52 Week High | $10.24 | $3.25 |
| Indicator | AEC | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 24.12 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $3.18 | N/A |
| Average True Range (ATR) | 0.19 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 7.91 | 0.00 |
Anfield Energy Inc is a mineral exploration and development company. This company focuses on uranium and vanadium development and near-term production. The exploration project of the company includes Shootaring Canyon Mill and Velvet-Wood and Slick Rock Uranium Project from Uranium One and The West Slope Project located in Montrose and San Miguel Counties in southwestern Colorado. The company's geographical segments are Canada and the United States.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.